Researchers find little proteins which may lessen aggravation brought about by COVID-19 Kumar Jeetendra | July 5, 2020 Researchers have found a new drug which they claim could possibly be practical to combat inflammation of all varieties, an improvement that might help in fighting aggravated immune response in respiratory disorders like COVID-19. The therapeutic, described at the journal Cell Tales, is known as TAT CARMIL1, and it’s actually a combination of two naturally …
China’s Sinovac begins late stage preliminaries for its COVID-19 antibody Kumar Jeetendra | July 7, 2020 China’s Sinovac Biotech is starting Phase III trials of its potential coronavirus vaccine in Brazil, ” said on Monday, becoming among three companies to transfer to the late stages at the race to develop an inoculation against the disorder. It follows a fast-track approval for the trials by Brazilian labs last week. Sinovac stated the …
Baxter India gets CDSCO gesture for utilization of its Oxiris channel in COVID-19 treatment Kumar Jeetendra | July 7, 2020 Healthcare firm Baxter India on Tuesday said it has received consent from the Central Drugs Standard Control Organisation (CDSCO) for the usage of its Oxiris blood purification filter to the treatment of COVID-19 patients. The filter is meant to be utilised in the seriously ill COVID-19 patients needing blood purification where excess inflammatory mediators are …
Indoor airborne spread of virus possible: WHO Kumar Jeetendra | July 10, 2020 The World Health Organisation (WHO) has declared that the risk that the book coronavirus, which induces COVID-19, could be dispersed in the atmosphere under specific conditions — after over 200 scientists urged the bureau to achieve that. In an open letter released this week in a diary, two scientists in Australia and the US composed …
COVID-19 side effects outside lungs decoded Kumar Jeetendra | July 12, 2020 Scientists, for example those with Indian-origin, have given the first extensive breakdown of COVID-19’s effects beyond the lungs, also have advocated that physicians treat this like a multisystem disorder with indicators such as blood clots, kidney failure, and neurological disorders such as delirium. “I had been on the frontlines directly from the start. I discovered …
UCI researchers develop novel molecule for COVID-19 treatment Kumar Jeetendra | August 6, 2020 When the coronavirus pandemic struck, nearly everyone in the University of California, Irvine — and colleges across the country — had to abandon campus. That’s because his laboratory, which designs and constructs chemical molecules, had the ideal equipment to aid in the international push to locate remedies for COVID-19. Nowick’s group set to work in …
Protein-based COVID-19 vaccine trial launched by Sanofi and GSK Kumar Jeetendra | September 3, 2020 French drugmaker Sanofi and its British peer GSK have begun a clinical trial for a protein-based COVID-19 vaccine candidate, as pharmaceutical firms race to develop treatments against the coronavirus pandemic. Sanofi and GSK said in a joint statement on Thursday they’d begun the”Stage 1/2″ trial for their adjuvanted COVID-19 vaccine, and that they expect to …
Brazil eyes Covid antibody rollout in January: Minister Kumar Jeetendra | September 9, 2020 Brazil’s acting Health Minister Eduardo Pazuello stated on Tuesday that a COVID-19 vaccine could be rolled out for all Brazilians in January 2021. “We’re closing contracts with vaccine manufacturers and the forecast is that a vaccine will arrive for us starting in January next year and we will begin vaccinating everybody,” Eduardo Pazuello said in …
VINCOV-19, an antidote, and a cure against COVID-19, successfully completes Phase 2 Clinical Trials Kumar Jeetendra | October 13, 2022 VINS Bioproducts Limited, a leading immunological company, based in Hyderabad, in collaboration with the Centre for Cellular and Molecular Biology (CCMB) and the University of Hyderabad (UoH), announced the successful completion of Phase 2 Clinical Trials of VINCOV-19, India’s first antidote and a cure against SARS-CoV-2 virus. VINCOV-19 is now ready for market authorization and …
